- Greenwich stocks skyrocketed by 998 per cent on Wednesday riding on the back of positive results for breast cancer immunotherapy study. The stocks are up 1263 per cent month-to-date.
- Xenetic stocks jumped by over 193 per cent on Wednesday after its partner PJSC Pharmsynthez reported positive results from ongoing treatment trial for anemia in patients with persistent kidney ailments.
Biopharmaceutical company Greenwich LifeSciences (GLSI: US or NASDAQ: GLSI) stocks rocketed over 998 per cent on Wednesday, December 9, after announcing that it developed immunotherapy to avert the return of breast cancer among survivors.
Stocks of another biopharma firm Xenetic Biosciences, Inc. (XBIO: US or NASDAQ: XBIO) jumped nearly 193.5 per cent on Wednesday, after reporting positive results from Phase 3 trial of Epolong. The firm’s partner PJSC Pharmsynthez reported the results from its pivotal Epolong study, which uses PolyXen®, a tech platform to enhance treatment for anemia in patients with persistent kidney ailments.
Let us take a glance at these two biotech companies:
Greenwich LifeSciences Inc. (GLSI: US or Nasdaq: GLSI)
Current Stock Price: US$ 57.10
This bio-pharmaceutical firm engages in the advancement of immunotherapy to avoid breast cancer recurrence. The company published a poster for its GP2 Phase IIb clinical study presented at the San Antonio Breast Cancer Symposium virtually.
Kaplan Meier analysis of infection-free endurance for patients treated with GP2 immunotherapy indicated 100 per cent survival following operation and Herceptin treatment over an average of 5 years of re-checkup, the company said in a statement.
The medical stock has zoomed nearly 1263 per cent in the last one month. The stock has added over 893 per cent growth since its September 26 listing this year.
Its 10-day average stock trading volume is 1.8 million.
The stock’s current price-to-book (P/B) ratio stands at 146.41, and its current market cap is approximately US$ 686 million, as per data available on the TMX portal.
Greenwich LifeSciences Stock’s One-Month Performance (Source: Refinitiv, Thomson Reuters)
Xenetic Biosciences, Inc. (XBIO: US or NASDAQ: XBIO)
Current Stock Price: US$ 3.17
The biopharma company is developing XCART™, a customized chimeric antigen receptor (CAR)-T tech platform for patient-specific tumor neoantigen.
The medical tech stocks have yielded nearly 128 per cent returns year-to-date (YTD) and soared over 264 per cent in the last one month.
Xenetic’s 10-day average stock trading volume has surged to 18.8 million units. Its present 30-day average volume stands at 6.42 million units.
Its current P/B ratio is 1.144, and price-to-cashflow (P/CF) is 10.40, as per the TMX portal.
The company posted a net loss of nearly US$ 9.7 million for the nine months ended September 30, 2020, compared to a net loss of almost US$ 11.6 million for the same period a year ago. The biopharma company reported working capital of US$ 7.2 million as of September 30, 2020, against US$ 9.7 million as of December 31, 2019.